| |
Newsroom >
Business
>
Markets
>
New Low Dose Protease Inhibitor Discovery for HIV-AIDS Treatment
New Low Dose Protease Inhibitor Discovery for HIV-AIDS Treatment
Narhex Australia founding Director and CEO John W. Majewski Looks to Garner Funding Assistance from Indiegogo for the Final Roll Out of His Revolutionary Low Dose Protease Inhibitor for HIV-AIDS Treatment.
Avalon,
IL,
United States of America
(sardnews.org)
22/10/2014
New Low Dose Protease Inhibitor Discovery for HIV-AIDS Treatment.
Narhex Australia, founding Director and CEO John W. Majewski Looks to Garner Funding Assistance from Indiegogo for the Final Roll Out of His companies Revolutionary Low Dose Protease Inhibitor for HIV-AIDS Treatment.
All are invited to John Majewski and team as a supporter to finalize the development of the last stages of a world class new anti-viral drug for treating HIV/AIDS.
Sydney, Australia October 19, 2014
John Majewski has put all his resources on the line to make a difference to people dying well before their time through no fault of their own. As the CEO and founder of Narhex Australia, John and his team has utilized the profits from their traditional Skin Treatment products to discover a new small molecule anti-viral DG 17 Prodrug for the treatment of HIV/AIDS victims.
The HIV population of North America and Latin America has been estimated at 2.9 million people. The US Agency for International Development estimated an HIV population of about 200,000 in Mexico.
Protease inhibitors are molecules designed specifically to block the viral protease by locking up the active site of the protease, rendering it nonfunctional and thus unable to cleave proteins that are essential to viral reproduction and further infection.
After more than a decade of privately funded research, testing and trials, John's objective is to work through the final clinical trials and to register Narhex DG 17 Prodrug, first in Mexico, followed by USA and other countries. Although John has set the target goal at $1,150,000, they will require a total of US $8 million over the coming 12-15 months. The funds will be used first for clinical trial design, regulatory application along with the required documentation as well as preparing dosage formulations.
Crowdfunding Indiegogo campaign page: http://igg.me/at/DG17/
About Narhex Australia: Narhex Australia is a privately held company since 1987, completely independent from the major pharmaceutical companies. The Narhex anti-viral research division under the direction of Dr Damian Grobelny led to the discovery of several compounds with enhanced HIV protease inhibitory ability, providing Narhex with the exciting opportunity to develop the Narhex Protease Inhibitor DG 17 Prodrug and its other compounds and so participate in the field of HIV/AIDS treatment research.
Contact: Tel: +61 2 9979 9666 Mobile: 61409 500575
John Majewski johnm@narhexmax.com.au
Website: www.narhexhivaids.com
Indiegogo Low Dose Protease Inhibitor Discovery campaign http://igg.me/at/DG17/
John Majewski and his Narhex team are in the last stages to finalize the development of the last stages of a world class new anti-viral drug for treating HIV/AIDS for registraton in Mexico MoH. http://igg.me/at/DG17/ http://narhexhivaids.com
About Narhex Australia Pty Ltd.
Mail: PO Box 359, Avalon, NSW, 2107 Australia Narhex Australia Pty Ltd.
|